Our results suggest that CD133 is a potential target for drug delivery to osteosarcoma CSCs and that it is possible to significantly inhibit the osteosarcoma growth by killing CD133(+) osteosarcoma CSCs. We demonstrated that Ap-SAL-NP have the potential to target and kill CD133(+) osteosarcoma CSCs.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: